Zikun Peng

Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial

Xingyu Liu, Wei Zhang, Ming Li, 2022, BMJ Open.

Oncological big data platforms for promoting digital competencies and professionalism in Chinese medical students: a cross-sectional study

Xingyu Liu, Yang Yu, Ming Li, 2022, BMJ Open.

Does the primary treatment sequence affect post‐relapse survival in recurrent epithelial ovarian cancer? A real‐world multicentre retrospective study

Ming Li, Qi Zhou, Ting Hu, 2022, BJOG : an international journal of obstetrics and gynaecology.

The first Chinese National Union of Real‐world Gynaecological Oncology Research and Patient Management Platform: A retrospective study

Wei Wang, Ming Li, Ting Hu, 2022, BJOG : an international journal of obstetrics and gynaecology.

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study

Ming Li, Qi Zhou, Ting Hu, 2023, Journal of Ovarian Research.

Development and validation of a nomogram to predict cancer-specific survival of mucinous epithelial ovarian cancer after cytoreductive surgery

Ming Li, Qi Zhou, Ting Hu, 2023, Journal of Ovarian Research.

PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities.

Ming Li, Zikun Peng, Qing-cui Gao, 2023, Drug discovery today.

Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors

Gang Chen, Sen Xu, X. Jiao, 2024, Cell.